Latest Administration News

Bounty Oil & Gas, through its joint venture operator Asset Energy, has initiated a judicial review against the refusal to vary and extend the PEP-11 offshore petroleum exploration permit. The legal challenge could reshape the future of this key Sydney Basin asset.

Advent Energy, in which MEC Resources holds a significant stake, is pursuing a judicial review against the federal government's refusal to extend the PEP-11 offshore petroleum permit. This legal move could reshape the future of the project and its stakeholders.

Praemium Limited has announced that no earn out payment is due for the first period following its acquisition of the OneVue Platform Business, as funds under administration fell below the $3 billion threshold. Despite client terminations, the company remains confident in its earnings and synergy targets.

Bravura Solutions has received a final Class Ruling from the Australian Taxation Office clarifying the tax treatment of its recent $0.163 per share capital return, providing certainty for shareholders holding shares on capital account.

Astute Metals NL has announced a significant JORC-compliant Exploration Target for its Red Mountain Lithium Project in Nevada, highlighting substantial lithium potential and outlining aggressive drilling plans for 2025.

RareX has finalized a critical access agreement with Deep Yellow and secured two additional licenses, enabling a fully optimised drilling program targeting carbonatite intrusions at the Khaleesi Project.

Titanium Sands Limited has raised $500,000 through a placement to advance environmental approvals and mining licence progress for its Mannar Island Heavy Mineral Project in Sri Lanka.

Island Pharmaceuticals has successfully completed patient dosing in the Phase 2b therapeutic arm of its PROTECT clinical trial for ISLA-101, targeting dengue fever treatment. High-level results are expected within two months, potentially advancing a significant antiviral candidate.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.

Suncorp Group Limited delivered a robust half-year performance with a $1.1 billion net profit, driven by favourable natural hazard conditions and the strategic sale of Suncorp Bank. The insurer plans a substantial $4.1 billion return to shareholders, underscoring its strong capital position and growth ambitions.

Sarama Resources has completed the second tranche of its A$2 million equity placement, issuing options to institutional investors after shareholder approval. The funds are earmarked for advancing exploration and supporting working capital.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.